← Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
📢 Press Releases
Date | Press release |
---|---|
2025-05-22 08:00:00 | New Novo Nordisk Initiatives Support Patient Access To Authentic, Fda-approved Wegovy® As Federal Ban On Mass Compounding Of \"semaglutide\" Takes Effect With all doses of fda-approved wegovy® fully available nationwide, it is illegal under us compounding laws to make or sell knockoff ’semaglutide’ drugs, with rare exceptions new, one-time $199 first-month offer for wegovy® available through june 30, 2025; offer designed to help new self-paying patients previously prescribed unapproved ’semaglutide’ start on fda-approved wegovy® ’choose the real thing’ campaign launching to raise awareness about the dangers of knockoff ’semaglutide’ novo nordisk intensifies legal actions aimed at protecting patients from risks and dangers associated with compounded ’semaglutide’ drugs and their foreign illicit active ingredients plainsboro, n.j. , may 22, 2025 /prnewswire/ -- today, as the us food and drug administration (fda) grace period for mass compounding of ’semaglutide’ expires, novo nordisk announced a series of initiatives to further support patient access to authentic, fda-approved wegovy® (semaglutide) injection 2.4 mg. |
2025-05-16 07:19:00 | Novo Nordisk A/s: Lars Fruergaard JØrgensen To Step Down As Ceo Of Novo Nordisk BagsvÆrd, denmark, 16 may 2025 – novo nordisk today announced changes to its executive leadership and board of directors. as per mutual agreement with the novo nordisk board, lars fruergaard jØrgensen will step down from his role as ceo of novo nordisk. |
2025-05-12 02:01:00 | Novo Nordisk A/s: Once-weekly Sogroya® (somapacitan) Is An Efficacious And Well-tolerated Long-acting Growth Hormone In Children With Growth Disorders: Results From Real8 Phase 3 Basket Study Presented At The Joint Congress Of Espe And Ese BagsvÆrd, denmark, 12 may 2025 – novo nordisk today presented data from the phase 3 real8 basket study, which showed that once-weekly sogroya® (somapacitan) was non-inferior to the once-daily growth hormone norditropin® (somatropin) in improving yearly growth rate (as measured by height velocity [hv] at week 52) in pre-pubertal children born small for gestational age (sga)1, or with noonan syndrome (ns)2, or with idiopathic short stature (iss)3. in addition, superiority was achieved for once-weekly sogroya® versus daily growth hormone in children with ns2, as well as compared to lower doses of daily growth hormone in children born sga1. |
2025-05-09 07:22:00 | Novo Nordisk A/s: Trading In Novo Nordisk Shares By Board Members, Executives And Associated Persons BagsvÆrd, denmark, 9 may 2025 — this company announcement discloses the data of the transaction(s) made in novo nordisk shares by the company’s board members, executives and their associated persons in accordance with article 19 of regulation no. 596/2014 on market abuse. |
2025-05-07 01:30:00 | Novo Nordisk’s Sales Increased By 19% In Danish Kroner And By 18% At Constant Exchange Rates To Dkk 78.1 Billion In The First Three Months Of 2025 7 may 2025 - financial report for the period 1 january 2025 to 31 march 2025 |
2025-05-06 08:00:00 |
|
2025-04-09 15:45:00 |
|
2025-04-03 02:00:00 |
|
2025-03-29 14:33:00 |
|
2025-03-28 09:11:00 |
|
2025-03-27 11:17:00 |
|
2025-03-25 16:30:00 |
|
2025-03-25 13:30:00 |
|
2025-03-25 11:15:00 |
|
2025-03-25 11:00:00 |
|

📰 Browse additional press releases for Novo Nordisk!
Sign up for free or log in📘 Claim your free eBook: "The Checklist Value Investor — A Smarter Way to Pick Stocks"